Biological therapies for atopic dermatitis: An update (Review)
- Authors:
- Diana Deleanu
- Irena Nedelea
-
Affiliations: Allergology and Immunology Discipline, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, 400058 Cluj-Napoca, Romania - Published online on: November 19, 2018 https://doi.org/10.3892/etm.2018.6989
- Pages: 1061-1067
This article is mentioned in:
Abstract
|
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M and Eckert L: Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 73:1284–1293. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK and Williams H: ISAAC Phase Three Study Group: Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 368:733–743. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nutten S: Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab. 66 Suppl 1:8–16. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ and Abramson MJ: Atopic dermatitis and the atopic march revisited. Allergy. 69:17–27. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mortz CG, Andersen KE, Dellgren C, Barington T and Bindslev-Jensen C: Atopic dermatitis from adolescence to adulthood in the TOACS cohort: Prevalence, persistence and comorbidities. Allergy. 70:836–845. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Constantin MM: Value and impact of patch testing in patients with allergic contact dermatitis. Rom J Lab Med. 20:101–106. 2012. | |
|
Montes-Torres A, Llamas-Velasco M, Pérez-Plaza A, Solano-López G and Sánchez-Pérez J: Biological Treatments in Atopic Dermatitis. J Clin Med. 4:593–613. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Milgrom H, Fick RB Jr, Su JQ, Reimann JD, Bush RK, Watrous ML and Metzger WJ: Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med. 341:1966–1973. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Salvi SS and Babu KS: Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med. 342:1292–1293. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Wu KC and Jabbar-Lopez ZK: Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria. J Invest Dermatol. 135:13–15. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, Mathelier-Fusade P, Meshkova RY, Zuberbier T, Metz M, et al: The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 71:780–802. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Vashisht P and Casale T: Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther. 13:933–945. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Loizou D, Enav B, Komlodi-Pasztor E, Hider P, Kim-Chang J, Noonan L, Taber T, Kaushal S, Limgala R, Brown M, et al: A pilot study of omalizumab in eosinophilic esophagitis. PLoS One. 10:e01134832015. View Article : Google Scholar : PubMed/NCBI | |
|
Lieberman JA and Chehade M: Use of omalizumab in the treatment of food allergy and anaphylaxis. Curr Allergy Asthma Rep. 13:78–84. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
El-Qutob D: Off-label uses of omalizumab. Clin Rev Allergy Immunol. 50:84–96. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wright JD, Chu HM, Huang CH, Ma C, Chang TW and Lim C: Structural and physical basis for anti-IgE therapy. Sci Rep. 5:115812015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Lester P, Builder S and Shire SJ: Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry. 34:10474–10482. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Brownell J and Casale TB: Anti-IgE therapy. Immunol Allergy Clin North Am. 24:551–568. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Sallmann E, Reininger B, Brandt S, Duschek N, Hoflehner E, Garner-Spitzer E, Platzer B, Dehlink E, Hammer M, Holcmann M, et al: High-affinity IgE receptors on dendritic cells exacerbate Th2-dependent inflammation. J Immunol. 187:164–171. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R and Liu YJ: Reciprocal control of T helper cell and dendritic cell differentiation. Science. 283:1183–1186. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Noga O, Hanf G and Kunkel G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 131:46–52. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kitaura J, Song J, Tsai M, Asai K, Maeda-Yamamoto M, Mocsai A, Kawakami Y, Liu FT, Lowell CA, Barisas BG, et al: Evidence that IgE molecules mediate a spectrum of effects on mast cell survival and activation via aggregation of the FcepsilonRI. Proc Natl Acad Sci USA. 100:12911–12916. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Noga O, Hanf G, Brachmann I, Klucken AC, Kleine-Tebbe J, Rosseau S, Kunkel G, Suttorp N and Seybold J: Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 117:1493–1499. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lane JE, Cheyney JM, Lane TN, Kent DE and Cohen DJ: Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 54:68–72. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Thaiwat S and Sangasapaviliya A: Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol. 29:357–360. 2011.PubMed/NCBI | |
|
Fernández-Antón Martínez MC, Leis-Dosil V, Alfageme-Roldán F, Paravisini A, Sánchez-Ramón S and Suárez Fernández R: Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr. 103:624–628. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT and Nadeau KC: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 162:89–93. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I and Grohé C: Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: One year follow-up of omalizumab therapy. Eur J Med Res. 16:407–410. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim DH, Park KY, Kim BJ, Kim MN and Mun SK: Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 38:496–500. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Romano C, Sellitto A, De Fanis U, Balestrieri A, Savoia A, Abbadessa S, Astarita C and Lucivero G: Omalizumab for difficult-to-treat dermatological conditions: Clinical and immunological features from a retrospective real-life experience. Clin Drug Investig. 35:159–168. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J and Hussain I: Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 55:168–170. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Heil PM, Maurer D, Klein B, Hultsch T and Stingl G: Omalizumab therapy in atopic dermatitis: Depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges. 8:990–998. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Krathen RA and Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol. 53:338–340. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wang HH, Li YC and Huang YC: Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. J Allergy Clin Immunol. 138:1719–1722. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hotze M, Baurecht H, Rodríguez E, Chapman-Rothe N, Ollert M, Fölster-Holst R, Adamski J, Illig T, Ring J and Weidinger S: Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy. 69:132–135. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Andreae DA and Wang J: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: A randomized, placebo-controlled clinical trial. Pediatrics. 134 Suppl 3:S1602014. View Article : Google Scholar : PubMed/NCBI | |
|
Shirley M: Dupilumab: First global approval. Drugs. 77:1115–1121. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hamilton JD, Ungar B and Guttman-Yassky E: Drug evaluation review: Dupilumab in atopic dermatitis. Immunotherapy. 7:1043–1058. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vella A, Teague TK, Ihle J, Kappler J and Marrack P: Interleukin-4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J Exp Med. 186:325–330. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Enelow R, Baramki DF and Borish LC: Inhibition of effector T lymphocytes mediated through antagonism of IL-4. J Allergy Clin Immunol. 113:560–562. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schleimer RP, Sterbinsky SA, Kaiser J, Bickel CA, Klunk DA, Tomioka K, Newman W, Luscinskas FW, Gimbrone MA Jr, McIntyre BW, et al: IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. J Immunol. 148:1086–1092. 1992.PubMed/NCBI | |
|
Tanaka T, Hitomi Y, Kambayashi Y, Hibino Y, Fukutomi Y, Shibata A, Sugimoto N, Hatta K, Eboshida A, Konoshita T, et al: The differences in the involvements of loci of promoter region and Ile50Val in interleukin-4 receptor A chain gene between atopic dermatitis and Japanese cedar pollinosis. Allergol Int. 61:57–63. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hackstein H, Hecker M, Kruse S, Bohnert A, Ober C, Deichmann KA and Bein G: A novel polymorphism in the 5 promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics. 53:264–269. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Hershey GK, Friedrich MF, Esswein LA, Thomas ML and Chatila TA: The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med. 337:1720–1725. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Tamura K, Suzuki M, Arakawa H, Tokuyama K and Morikawa A: Linkage and association studies of STAT6 gene polymorphisms and allergic diseases. Int Arch Allergy Immunol. 131:33–38. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS, Hansen KC and Leung DY: Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol. 128:2248–2258. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, Schneider L, Beck LA, Barnes KC and Leung DY: Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 120:150–155. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kim BE, Leung DY, Boguniewicz M and Howell MD: Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 126:332–337. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh FH, Lam BK, Penrose JF, Austen KF and Boyce JA: T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood-derived mast cells: Profound induction of leukotriene C(4) synthase expression by interleukin 4. J Exp Med. 193:123–133. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, et al: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 371:130–139. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, Ming JE, Radin AR, Krueger JG, Graham N, et al: Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 134:1293–1300. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Blakely K, Gooderham M and Papp K: Dupilumab, a monoclonal antibody for atopic dermatitis: A review of current literature. Skin Therapy Lett. 21:1–5. 2016.PubMed/NCBI | |
|
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, et al: Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: A randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 387:40–52. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tsianakas A, Luger TA and Radin A: Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial. Br J Dermatol. 178:406–414. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, et al: SOLO 1 and SOLO 2 investigators: Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 375:2335–2348. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Simpson EL: Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: Pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb). 7:243–248. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, et al: Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 389:2287–2303. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Eichenfield L, Flohr C, Simpson E, DeBusk K, Kin CY and Karl Y: Lebrikizumab improves patient-reported outcomes (PROs) in a phase 2 study in patients with atopic dermatitis. J Am Acad Dermatol. 76:AB423. 2017. View Article : Google Scholar | |
|
Hajar T, Gontijo JR and Hanifin JM: New and developing therapies for atopic dermatitis. An Bras Dermatol. 93:104–107. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Snast I, Reiter O, Hodak E, Friedland R, Mimouni D and Leshem YA: Are biologics efficacious in atopic dermatitis? A systematic review and meta-analysis. Am J Clin Dermatol. 19:145–165. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, Krieg T, Stanzel S, Heinrich PC and Merk HF: Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 118:930–937. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewicz M, Yao L, Storey H, LeCiel C, Harder B and Gross JA: IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 117:418–425. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, Galus R, Etoh T, Mihara R, Yoshida H, et al: XCIMA Study Group: Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med. 376:826–835. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT and Gordon KB: PHOENIX 1 study investigators: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 371:1665–1674. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Maeda S, Hayami Y, Naniwa T and Ueda R: The Th17/IL-23 axis and natural immunity in psoriatic arthritis. Int J Rheumatol. 2012:5396832012. View Article : Google Scholar : PubMed/NCBI | |
|
Bromley SK, Larson RP, Ziegler SF and Luster AD: IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice. PLoS One. 8:e581962013. View Article : Google Scholar : PubMed/NCBI | |
|
Leonardi S, Cuppari C, Manti S, Filippelli M, Parisi GF, Borgia F, Briuglia S, Cannavò P, Salpietro A, Arrigo T, et al: Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome (AEDS): Association with clinical severity and phenotype. Allergy Asthma Proc. 36:74–81. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Agusti-Mejias A, Messeguer F, García R and Febrer I: Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 25:368–370. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Puya R, Alvarez-López M, Velez A, Casas Asuncion E and Moreno JC: Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 51:115–116. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fernández-Antón Martínez MC, Alfageme Roldán F, Ciudad Blanco C and Suárez Fernández R: Ustekinumab in the treatment of severe atopic dermatitis: A preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 105:312–313. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Shroff A and Guttman-Yassky E: Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 1:25–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Samorano LP, Hanifin JM, Simpson EL and Leshem YA: Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol. 30:522–523. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wlodek C, Hewitt H and Kennedy CT: Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol. 41:625–627. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, Peng X, Estrada YD, Nakajima S, Honda T, et al: The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 136:1254–1264. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dastidar SG, Rajagopal D and Ray A: Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 8:364–372. 2007.PubMed/NCBI | |
|
Hanifin JM and Chan SC: Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol. 105 Suppl 1:84S–88S. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Souness JE, Aldous D and Sargent C: Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 47:127–162. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, et al: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 159:842–855. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Samrao A, Berry TM, Goreshi R and Simpson EL: A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol. 148:890–897. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Abrouk M, Farahnik B, Zhu TH, Nakamura M, Singh R, Lee K, Lucking SM, Blossom J, Liao W, Koo J, et al: Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 77:177–180. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Saporito RC and Cohen DJ: Apremilast use for moderate-to-severe atopic dermatitis in pediatric patients. Case Rep Dermatol. 8:179–184. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, Hijnen DJ, Plötz S, Knol EF, Kapp A, et al: Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 60:693–696. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Oldhoff JM, Darsow U, Werfel T, Bihari IC, Katzer K, Laifaoui J, Plötz S, Kapp A, Knol EF, Bruijnzeel-Koomen CA, et al: No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol. 141:290–294. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Buka RL, Resh B, Roberts B, Cunningham BB and Friedlander S: Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 53:358–359. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobi A, Antoni C, Manger B, Schuler G and Hertl M: Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol. 52:522–526. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Boguniewicz M: Biologic therapy for atopic dermatitis: Moving beyond the practice parameter and guidelines. J Allergy Clin Immunol Pract. 5:1477–1487. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
McDonald BS, Jones J and Rustin M: Rituximab as a treatment for severe atopic eczema: Failure to improve in three consecutive patients. Clin Exp Dermatol. 41:45–47. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Roekevisch E, Spuls PI, Kuester D, Limpens J and Schmitt J: Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J Allergy Clin Immunol. 133:429–438. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Boguniewicz M, Jaffe HS, Izu A, Sullivan MJ, York D, Geha RS and Leung DY: Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med. 88:365–370. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G, et al: Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol. 28:189–197. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider LC, Baz Z, Zarcone C and Zurakowski D: Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. Ann Allergy Asthma Immunol. 80:263–268. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Stevens SR, Hanifin JM, Hamilton T, Tofte SJ and Cooper KD: Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol. 134:799–804. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J and Simpson E: Efalizumab for severe atopic dermatitis: A pilot study in adults. J Am Acad Dermatol. 56:222–227. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Moul DK, Routhouska SB, Robinson MR and Korman NJ: Alefacept for moderate to severe atopic dermatitis: A pilot study in adults. J Am Acad Dermatol. 58:984–989. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, Ruzicka T, Brehler R, Wolf H, Schnitker J, et al: Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: A multi-centre, randomized, dose-response study. Allergy. 61:202–205. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Bae JM, Choi YY, Park CO, Chung KY and Lee KH: Efficacy of allergen-specific immunotherapy for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 132:110–117. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Novak N, Bieber T, Hoffmann M, Fölster-Holst R, Homey B, Werfel T, Sager A and Zuberbier T: Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 130:925–31.e4. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gendelman SR and Lang DM: Specific immunotherapy in the treatment of atopic dermatitis: A systematic review using the GRADE system. Ann Allergy Asthma Immunol. 111:555–561. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Qin YE, Mao JR, Sang YC and Li WX: Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 53:650–655. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pajno GB, Caminiti L, Vita D, Barberio G, Salzano G, Lombardo F, Canonica GW and Passalacqua G: Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 120:164–170. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mastrandrea F, Serio G, Minelli M, Minardi A, Scarcia G, Coradduzza G and Parmiani S: Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients. Allergol Immunopathol (Madr). 28:54–62. 2000.PubMed/NCBI | |
|
Darsow U: Allergen-specific immunotherapy for atopic eczema: Updated. Curr Opin Allergy Clin Immunol. 12:665–669. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bissonnette R, Papp KA, Poulin Y, Gooderham M, Raman M, Mallbris L, Wang C, Purohit V, Mamolo C, Papacharalambous J, et al: Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial. Br J Dermatol. 175:902–911. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, Eichenfield LF, Forsha DW, Rees WC, Simpson EL, et al: Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 75:494–503.e6. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS and Weiner ES: Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 107:51–56. 1996. View Article : Google Scholar : PubMed/NCBI |
